Photocure

Price Chart

Risk-Adjusted Performance

Also Listed On

Photocure (PHO) Price Performance

Photocure (PHO) trades on Oslo Stock Exchange in NOK. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at NOK69.50, up 5.78% from the previous close.

Over the past year, PHO has traded between a low of NOK49.40 and a high of NOK79.00. The stock has gained 27.8% over this period. It is currently 12.0% below its 52-week high.

Photocure has a market capitalization of $1.75B, with a price-to-earnings ratio of 733.75.

About Photocure

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, rest of the Europe, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.